ストックスクリーナーアプリを入手
26.79
0.71%
0.19
アフターアワーズ：
26.79
前日終値:
$26.60
開ける：
$26.64
24時間の取引高:
2.38M
Relative Volume:
3.10
時価総額：
$2.32B
収益：
$23.38M
当期純損益:
$-155.22M
株価収益率:
-18.48
EPS:
-1.45
ネットキャッシュフロー:
$-134.36M
1週間 パフォーマンス:
+0.56%
1か月 パフォーマンス:
-11.35%
6か月 パフォーマンス:
-35.26%
1年 パフォーマンス:
-15.22%
1日の値動き範囲:
$26.30
$27.50
1週間の範囲:
$25.20
$27.50
52週間の値動き範囲:
$25.20
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
名前
Ideaya Biosciences Inc
セクター
電話
650-443-6209
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| IDYA | 26.79 | 2.32B | 23.38M | -155.22M | -134.36M | -1.45 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-08 | 開始されました | SVB Securities | Outperform |
| 2023-05-24 | 開始されました | Goldman | Buy |
| 2023-04-24 | アップグレード | Stifel | Hold → Buy |
| 2023-03-23 | 開始されました | Berenberg | Buy |
| 2023-02-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-28 | 開始されました | CapitalOne | Overweight |
| 2022-10-27 | 開始されました | Citigroup | Buy |
| 2022-08-15 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-10 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-11 | 開始されました | Guggenheim | Buy |
| 2020-10-07 | 開始されました | Wedbush | Outperform |
| 2020-09-01 | 開始されました | Northland Capital | Outperform |
| 2020-07-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-06 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-13 | 開始されました | ROTH Capital | Buy |
| 2019-10-17 | 開始されました | Oppenheimer | Outperform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-17 | 開始されました | Citigroup | Buy |
| 2019-06-17 | 開始されました | JP Morgan | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
すべてを表示
Ideaya Biosciences Inc (IDYA) 最新ニュース
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Yahoo Finance
Jennison Associates LLC Buys 561,404 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com
Quest Partners LLC Increases Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - MSN
Finansavisen - Finansavisen
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com
IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat
Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma
IDEAYA Biosciences Taps Former Gilead Oncology VP as Chief Commercial Officer | IDYA Stock News - StockTitan
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India
500: Something went wrong - Investing.com Canada
Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK
Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com
IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia
(IDYA) Investment Analysis - Stock Traders Daily
FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace
IDEAYA Biosciences Announces Participation Jefferies London | Trending From Our Network - Chicago Star Media
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve
Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online
IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media
Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat
90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat
The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St
Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat
FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat
Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
/C O R R E C T I O N — IDEAYA Biosciences, Inc./ - Morningstar
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times
Ideaya Biosciences Inc (IDYA) 財務データ
収益
当期純利益
現金流量
EPS
Ideaya Biosciences Inc (IDYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Throne Jason | Chief Legal Officer |
Jun 27 '24 |
Option Exercise |
7.77 |
53,484 |
415,587 |
63,484 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Option Exercise |
12.86 |
28,500 |
366,510 |
28,500 |
| WHITE MICHAEL ANTHONY | Chief Scientific Officer |
May 29 '24 |
Sale |
36.24 |
28,500 |
1,032,884 |
0 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Option Exercise |
4.31 |
83,856 |
361,419 |
761,743 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Option Exercise |
4.31 |
56,711 |
244,424 |
734,598 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Option Exercise |
4.31 |
34,433 |
148,406 |
712,320 |
| Hata Yujiro S | President and CEO |
May 15 '24 |
Sale |
42.90 |
83,856 |
3,597,756 |
677,887 |
| Hata Yujiro S | President and CEO |
May 14 '24 |
Sale |
41.61 |
56,711 |
2,359,780 |
677,887 |
| Hata Yujiro S | President and CEO |
May 16 '24 |
Sale |
41.81 |
34,433 |
1,439,754 |
677,887 |
| Ruiz Briseno Andres | See Remarks |
Feb 09 '24 |
Sale |
46.02 |
2,000 |
92,045 |
24,531 |
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):